Sunshine Biopharma Inc
SBFMW0.210USD
-0.010-4.50%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
0.00Cap. mercado
--P/E TTM
Más Datos de Sunshine Biopharma Inc Compañía
Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has over 32 additional generic prescription drugs. In addition, the Company is conducting a proprietary drug development program which consists of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio of pharmaceutical products consisting of approximately 61 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.
Información de la empresa
Símbolo de cotizaciónSBFMW
Nombre de la empresaSunshine Biopharma Inc
Fecha de salida a bolsaAug 15, 2008
Director ejecutivoDr. Steve N. Slilaty
Número de empleados- -
Tipo de seguridadCompany Warrant
Fin del año fiscal- -
Dirección333 Las Olas Way
CiudadFORT LAUDERDALE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal33301
Teléfono19543300684
Sitio Webhttps://www.sunshinebiopharma.com/
Símbolo de cotizaciónSBFMW
Fecha de salida a bolsaAug 15, 2008
Director ejecutivoDr. Steve N. Slilaty
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Dr. Andrew M. Keller
Dr. Andrew M. Keller
Independent Director
Independent Director
--
--
Mr. Marc Beaudoin
Mr. Marc Beaudoin
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Science Officer, Director
Chief Science Officer, Director
--
--
Mr. Malek Chamoun
Mr. Malek Chamoun
Chief Development Officer
Chief Development Officer
--
--
Mr. Michel Roy
Mr. Michel Roy
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. David Natan
Mr. David Natan
Independent Director
Independent Director
--
--
Mr. Camille Sebaaly
Mr. Camille Sebaaly
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Dr. Andrew M. Keller
Dr. Andrew M. Keller
Independent Director
Independent Director
--
--
Mr. Marc Beaudoin
Mr. Marc Beaudoin
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Science Officer, Director
Chief Science Officer, Director
--
--
Mr. Malek Chamoun
Mr. Malek Chamoun
Chief Development Officer
Chief Development Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 18 de may
Actualizado: dom., 18 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Other
100.00%
Accionistas
Accionistas
Proporción
Other
100.00%
Tipos de accionistas
Accionistas
Proporción
Other
100.00%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
5
60.37K
0.00%
+5.15K
2025Q1
5
60.37K
0.00%
+5.15K
2024Q4
5
42.72K
0.00%
-18.68K
2024Q3
5
47.02K
0.00%
-38.45K
2024Q2
6
87.95K
0.00%
-8.56K
2024Q1
6
84.02K
0.00%
-7.28K
2023Q4
6
78.99K
0.00%
-17.09K
2023Q3
6
83.78K
0.00%
-60.47K
2023Q2
6
144.24K
0.00%
+102.73K
2023Q1
5
41.52K
0.00%
-13.18K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Citadel Advisors LLC
30.55K
0%
-10.89K
-26.28%
Mar 31, 2025
UBS Financial Services, Inc.
29.73K
0%
+28.44K
+2206.52%
Mar 31, 2025
BofA Global Research (US)
--
0%
-200.00
-100.00%
Mar 31, 2024
Clear Street LLC
94.00
0%
+94.00
--
Mar 31, 2025
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
